Han-Joon Kim

List of Publications by Year
in descending order

207	3,836	159358	214527
papers	citations	30 h-index	47 g-index

209	209	209	4664
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism and Related Disorders, 2010, 16, 202-207.	1.1	161
2	Diffusion-Weighted Imaging Abnormalities in Wernicke Encephalopathy. Archives of Neurology, 2002, 59, 123.	4.9	140
3	Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. Journal of Neurology, 2008, 255, 1889-1894.	1.8	112
4	Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease. Movement Disorders, 2014, 29, 61-67.	2.2	103
5	Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. Journal of the Neurological Sciences, 2009, 287, 200-204.	0.3	82
6	Peripheral blood inflammatory markers in early Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2018, 58, 30-33.	0.8	73
7	Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 76-78.	1.1	69
8	An 8-Year Follow-up on the Effect of Subthalamic Nucleus Deep Brain Stimulation on Pain in Parkinson Disease. JAMA Neurology, 2015, 72, 504.	4.5	69
9	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain, 2020, 143, 1780-1797.	3.7	66
10	Survival of Korean patients with multiple system atrophy. Movement Disorders, 2011, 26, 909-912.	2.2	62
11	Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. Parkinsonism and Related Disorders, 2018, 51, 49-54.	1.1	61
12	Nonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinsonâ€™s Disease. Journal of Movement Disorders, 2015, 8, 83-91.	0.7	57
13	The Benefit of Subthalamic Deep Brain Stimulation for Pain in Parkinson Disease. Neurosurgery, 2012, 70, 18-24.	0.6	56
14	Clinical and imaging characteristics of dementia in multiple system atrophy. Parkinsonism and Related Disorders, 2013, 19, 617-621.	1.1	54
15	Parkinsonism in Spinocerebellar Ataxia. BioMed Research International, 2015, 2015, 1-11.	0.9	53
16	Diffusion-Weighted MRI and ^{99m}Tc-HMPAO SPECT in Delayed Relapsing Type of Carbon Monoxide Poisoning: Evidence of Delayed Cytotoxic Edema. European Neurology, 2004, 51, 98-103.	0.6	52
17	Putaminal serotonergic innervation. Neurology, 2015, 85, 853-860.	1.5	51
18	Musculoskeletal problems in Parkinson's disease: Neglected issues. Parkinsonism and Related Disorders, 2013, 19, 666-669.	1.1	50

#	Article	IF	Citations
19	Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. Journal of the Neurological Sciences, 2019, 401, 81-86.	0.3	49
20	CSF Î²-amyloid ₄₂ and risk of freezing of gait in early Parkinson disease. Neurology, 2019, 92, e40-e47.	1.5	45
21	Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A doubleâ€blind, randomized study. Movement Disorders, 2015, 30, 206-213.	2.2	44
22	REM sleep behavior disorder portends poor prognosis in Parkinsonâ€™s disease: A systematic review. Journal of Clinical Neuroscience, 2018, 47, 6-13.	0.8	43
23	REM sleep behavior disorder: Association with motor complications and impulse control disorders in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1081-1084.	1.1	42
24	Should genetic testing for SCAs be included in the diagnostic workup for MSA?. Neurology, 2014, 83, 1733-1738.	1.5	41
25	Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2013, 20, 964-969.	0.8	40
26	Motor Complications in Parkinson's Disease: 13â€Year Followâ€up of the CamPaIGN Cohort. Movement Disorders, 2020, 35, 185-190.	2.2	39
27	Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinsonâ€™s disease. Journal of Neurology, 2014, 261, 1090-1096.	1.8	38
28	Taste function in patients with Parkinson disease. Journal of Neurology, 2011, 258, 1076-1079.	1.8	37
29	Twoâ€year followâ€up on the effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson's disease. Movement Disorders, 2009, 24, 329-335.	2.2	33
30	Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy. Journal of Neurology, 2010, 257, 2065-2070.	1.8	33
31	The clinical impact of precise electrode positioning in STN DBS on three-year outcomes. Journal of the Neurological Sciences, 2013, 327, 25-31.	0.3	33
32	Validation of the Korean Version of the Scale for Outcomes in Parkinsonâ€™s Disease-Autonomic. Journal of Movement Disorders, 2017, 10, 29-34.	0.7	32
33	Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective. Experimental Neurobiology, 2013, 22, 77-83.	0.7	31
34	Bilateral Subthalamic Deep Brain Stimulation in Parkinson Disease Patients With Severe Tremor. Neurosurgery, 2010, 67, 626-632.	0.6	30
35	Phenotype analysis in patients with early onset Parkinsonâ€™s disease with and without parkin mutations. Journal of Neurology, 2011, 258, 2260-2267.	1.8	29
36	Leukocyte glucocerebrosidase and Î²-hexosaminidase activity in sporadic and genetic Parkinson disease. Parkinsonism and Related Disorders, 2016, 23, 99-101.	1.1	29

#	Article	IF	Citations
37	Fundamental limit of alpha-synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinsonâ€™s disease: Comparison with surgical specimens. Parkinsonism and Related Disorders, 2017, 44, 73-78.	1.1	29
38	A New Metabolic Network Correlated with Olfactory and Executive Dysfunctions in Idiopathic Rapid		

#	Article	IF	Citations
55	A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 3-8.	1.1	22
56	Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease. Parkinsonism and Related Disorders, 2019, 58, 35-39.	1.1	22
57	Abnormal activation of motor cortical network during phasic REM sleep in idiopathic REM sleep behavior disorder. Sleep, 2019, 42, .	0.6	22
58	Quantitative Gait Analysis Using a Pose-Estimation Algorithm with a Single 2D-Video of Parkinsonâ€™s Disease Patients. Journal of Parkinson's Disease, 2021, 11, 1271-1283.	1.5	22
59	STN DBS of Advanced Parkinson's Disease Experienced in a Specialized Monitoring Unit with a Prospective Protocol. Journal of Korean Neurosurgical Society, 2008, 44, 26.	0.5	22
60	Electrode Position and the Clinical Outcome after Bilateral Subthalamic Nucleus Stimulation. Journal of Korean Medical Science, 2011, 26, 1344.	1.1	21
61	Diagnosis and differential diagnosis of MSA: boundary issues. Journal of Neurology, 2015, 262, 1801-1813.	1.8	21
62	Non-cell-autonomous actions of Î±-synuclein: Implications in glial synucleinopathies. Progress in Neurobiology, 2018, 169, 158-171.	2.8	21
63	Nonrapid eye movement sleep electroencephalographic oscillations in idiopathic rapid eye movement sleep behavior disorder: a study of sleep spindles and slow oscillations. Sleep, 2021, 44, .	0.6	21
64	Relative contribution of SCA2, SCA3 and SCA17 in Korean patients with parkinsonism and ataxia. Parkinsonism and Related Disorders, 2011, 17, 338-342.	1.1	20
65	Delayed facial palsy after microvascular decompression for hemifacial spasm: friend or foe?. Journal of Neurosurgery, 2018, 129, 299-307.	0.9	20
66	Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinsonâ€™s disease. PLoS ONE, 2019, 14, e0221219.	1.1	20
67	Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism and Related Disorders, 2021, 91, 109-114.	1.1	20
68	Immunotherapy Targeting Neurodegenerative Proteinopathies: Î±-Synucleinopathies and Tauopathies. Journal of Movement Disorders, 2020, 13, 11-19.	0.7	20
69	Is pathological gambling in Parkinson's disease reduced by amantadine?. Annals of Neurology, 2011, 69, 213-214.	2.8	19
70	A mirâ€¡153 binding site variation in SNCA in a patient with Parkinson's disease. Movement Disorders, 2013, 28, 1755-1756.	2.2	19
71	Dry facts are not always inviting: a content analysis of Korean videos regarding Parkinsonâ€™s disease on YouTube. Journal of Clinical Neuroscience, 2017, 46, 167-170.	0.8	19
72	Identifying the Clusters within Nonmotor Manifestations in Early Parkinson's Disease by Using Unsupervised Cluster Analysis. PLoS ONE, 2014, 9, e91906.	1.1	19

#	Article	IF	Citations
73	Primary leptomeningeal lymphoma with long-term survival: a case report. Journal of Neuro-Oncology, 2000, 48, 47-49.	1.4	18
74	Initial cognitive dip after subthalamic deep brain stimulation in Parkinson disease. Journal of Neurology, 2013, 260, 2130-2133.	1.8	18
75	Parkin mutation and deep brain stimulation outcome. Journal of Clinical Neuroscience, 2014, 21, 107-110.	0.8	18
76	Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder. Movement Disorders, 2019, 34, 1739-1744.	2.2	18
77	Progression of Oropharyngeal Dysphagia in Patients with Multiple System Atrophy. Dysphagia, 2020, 35, 24-31.	1.0	18
78	Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinsonâ€™s Disease. Journal of Movement Disorders, 2018, 11, 30-34.	0.7	18
79	Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. Journal of Movement Disorders, 2019, 12, 103-112.	0.7	18
80	The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group. Journal of Clinical		

#	Article	IF	Citations
91	Various Motor and Non-Motor Symptoms in Early Multiple System Atrophy. Neurodegenerative Diseases, 2019, 19, 238-243.	0.8	14
92	Pneumonia risk and its associated factors in Parkinson's disease: A National Database Study. Journal of the Neurological Sciences, 2020, 415, 116949.	0.3	14
93	Amantadine and the Risk of Dyskinesia in Patients with Early Parkinsonâ€™s Disease: An Open-Label, Pragmatic Trial. Journal of Movement Disorders, 2018, 11, 65-71.	0.7	14
94	Phonological Agraphia After Superior Temporal Gyrus Infarction. Archives of Neurology, 2002, 59, 1314.	4.9	13
95	Increased Expression of Alpha-Synuclein by SNCA Duplication is Associated with Resistance to Toxic Stimuli. Journal of Molecular Neuroscience, 2012, 47, 249-255.	1.1	13
96	Apolipoprotein E Îµ4 genotype and risk of freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 81, 173-178.	1.1	13
97	Screening for MAPT and PGRN mutations in Korean patients with PSP/CBS/FTD. Parkinsonism and Related Disorders, 2010, 16, 305-306.	1.1	12
98	Bilateral Deep Brain Stimulation of the Subthalamic Nucleus under Sedation with Propofol and Fentanyl. PLoS ONE, 2016, 11, e0152619.	1.1	12
99	Emergence of non-motor fluctuations with reference to motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 54, 79-83.	1.1	12
100	Altered insular functional connectivity in isolated REM sleep behavior disorder: a data-driven functional MRI study. Sleep Medicine, 2021, 79, 88-93.	0.8	12
101	Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease. Movement Disorders, 2022, 37, 1535-1541.	2.2	12
102	SCA6 presenting with youngâ€onset parkinsonism without ataxia. Movement Disorders, 2012, 27, 1067-1068.	2.2	11
103	Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinsonâ€™s disease. BMC Neurology, 2013, 13, 113.	0.8	11
104	The Good, the Bad, and the Ugly of Medical Information on the Internet. Movement Disorders, 2018, 33, 754-757.	2.2	11
105	Objective measurement of limb bradykinesia using a marker-less tracking algorithm with 2D-video in PD patients. Parkinsonism and Related Disorders, 2020, 81, 129-135.	1.1	11
106	Severe Jabbing Headache Associated with Airplane Travel. Canadian Journal of Neurological Sciences, 2008, 35, 267-268.	0.3	10
107	Depression may negatively affect the change in freezing of gait following subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 133-136.	1.1	10
108	Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson's disease. Journal of the Neurological Sciences, 2020, 418, 117157.	0.3	10

#	Article	IF	Citations
109	Weight Change Is a Characteristic Non-Motor Symptom in Drug-NaÃ¯ve Parkinsonâ€™s Disease Patients with Non-Tremor Dominant Subtype: A Nation-Wide Observational Study. PLoS ONE, 2016, 11, e0162254.	1.1	10
110	Successful Pallidal Deep Brain Stimulation in a Patient with Childhood-Onset Generalized Dystonia with ANO3 Mutation. Journal of Movement Disorders, 2019, 12, 190-191.	0.7	10
111	Comorbid Depression Is Associated with a Negative Treatment Response in Idiopathic REM Sleep		

#	Article	IF	Citations
127	Urinary Symptoms and Urodynamic Findings in Patients with Spinocerebellar Ataxia. Cerebellum, 2020, 19, 483-486.	1.4	8
128	Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean		

#	Article	IF	Citations
145	Dural Arteriovenous Fistula-Associated Reversible Parkinsonism with Presynaptic Dopaminergic Loss. Journal of Movement Disorders, 2015, 8, 141-143.	0.7	6
146	Correlation of electrode position and clinical outcomes in globus pallidus stimulation for dystonia. Acta Neurochirurgica, 2017, 159, 1349-1355.	0.9	5
147	Acupuncture does not protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in a preclinical mouse model of Parkinsonâ€™s disease. NeuroReport, 2017, 28, 50-55.	0.6	5
148	Validation of the Korean Version of the Scales for Outcomes in Parkinson's Disease-Sleep. Journal of Korean Medical Science, 2018, 33, e14.	1.1	5
149	Chronological View of Peak and Diphasic Dyskinesia, Wearing Off and Freezing of Gait in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 741-747.	1.5	5
150	Negative Î±-synuclein pathology in the submandibular gland of patients carrying PRKN pathogenic variants. Parkinsonism and Related Disorders, 2020, 81, 179-182.	1.1	5
151	Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials. Journal of Neurology, 2022, 269, 62-71.	1.8	5
152	The probable REM sleep behavior disorder negatively affects health-related quality of life in Parkinson's disease with bilateral subthalamic nucleus stimulation. Parkinsonism and Related Disorders, 2020, 81, 136-139.	1.1	5
153	Patient-reported responses to medical treatment in primary dystonia. Journal of Clinical Neuroscience, 2020, 75, 242-244.	0.8	5
154	Arching deep brain stimulation in dystonia types. Journal of Neural Transmission, 2021, 128, 539-547.	1.4	5
155	Stiff-Person Syndrome: Case Series. Journal of Movement Disorders, 2014, 7, 19-21.	0.7	5
156	Young-Onset Parkinsonâ€™s Disease with Impulse Control Disorder Due to Novel Variants of F-Box Only Protein 7. Journal of Movement Disorders, 2020, 13, 225-228.	0.7	5
157	Isolated rapid eye movement sleep behavior disorder combined with obstructive sleep apnea: response to treatment and its associated factors. Sleep Medicine, 2022, 91, 75-83.	0.8	5
158	Effect of bilateral subthalamic deep brain stimulation on diphasic dyskinesia. Clinical Neurology and Neurosurgery, 2008, 110, 328-332.	0.6	4
159	Serum urate levels are not associated with survival in multiple system atrophy. Parkinsonism and Related Disorders, 2011, 17, 400-401.	1.1	4
160	Acupuncture: It is time for scientifically well-designed study. Parkinsonism and Related Disorders, 2013, 19, 831-832.	1.1	4
161	Hereditary geniospasm in a Korean family. Parkinsonism and Related Disorders, 2015, 21, 665-666.	1.1	4
162	Patient selected goals and satisfaction after bilateral subthalamic nucleus deep brain stimulation in Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2020, 76, 148-153.	0.8	4

#	Article	IF	Citations
163	Effects of Deep Brain Stimulation on Sleep-Wake Disturbances in Patients with Parkinson's Disease: A Narrative Review. Current Neuropharmacology, 2021, 19, 1716-1727.	1.4	4
164	A Case of Adrenoleukodystrophy Presenting as Progressive Cerebellar Dysfunction. Journal of Movement Disorders, 2009, 2, 91-94.	0.7	4
165	Myotonia Congenita Can Be Mistaken as Paroxysmal Kinesigenic Dyskinesia. Journal of Movement Disorders, 2018, 11, 49-51.	0.7	4
166	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		

#	Article	IF	Citations
181	Clinical differences in patients with Parkinsonâ€™s disease according to tandem gait performance. Journal of Clinical Neuroscience, 2019, 60, 93-95.	0.8	2
182	Investigation of Nocturnal Hypokinesia and Health-Related Quality of Life in Parkinsonian Patients with the Korean Version of the Nocturnal Hypokinesia Questionnaire. Journal of Movement Disorders, 2021, 14, 221-225.	0.7	2
183	Statin use and pneumonia risk in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 91, 124-127.	1.1	2
184	Apolipoprotein E Îµ4 is not associated with cognitive impairment in patients with idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2021, 92, 13-14.	1.1	2
185	Alternating Hemiplegia of Childhood in Korea: a Case Report. Journal of Korean Medical Science, 2020, 35, e203.	1.1	2
186	Bilateral Hemimasticatory spasm in a patient with hypereosinophilic syndrome. Parkinsonism and Related Disorders, 2021, 93, 55-57.	1.1	2
187	Data-driven subtype classification of patients with early-stage multiple system atrophy. Parkinsonism and Related Disorders, 2022, 95, 92-97.	1.1	2
188	Taste sense in patients with hemifacial spasm. Journal of Clinical Neuroscience, 2010, 17, 950-951.	0.8	1
189	Movement-induced focal tonicâ€“clonic seizure-like movements after ipsilateral basal ganglia hemorrhage. Journal of Clinical Neuroscience, 2011, 18, 285-286.	0.8	1
190	OFF-Rebound Dyskinesia in Subthalamic Nucleus Stimulation in Parkinson Disease. Canadian Journal of Neurological Sciences, 2011, 38, 768-771.	0.3	1
191	In need of something better than sleep. Lancet, The, 2013, 381, 598.	6.3	1
192	Considerations of Long-term Pain Evaluation Postâ€“ Deep Brain Stimulation Surgeryâ€”Reply. JAMA Neurology, 2015, 72, 1077.	4.5	1
193	A Patient with Myotonic Dystrophy Type 1 Presenting as Parkinsonism. Journal of Movement Disorders, 2018, 11, 145-148.	0.7	1
194	Tics in Paroxysmal Kinesigenic Dyskinesia. Movement Disorders Clinical Practice, 2019, 6, 502-503.	0.8	1
195	Musculoskeletal problems in PD patients have no association with socioeconomic status. Journal of Clinical Neuroscience, 2019, 70, 229-233.	0.8	1
196	Effect of unilateral subthalamic deep brain stimulation in highly asymmetrical Parkinsonâ€™s disease: 7-year follow-up. Journal of Neurosurgery, 2019, 131, 1508-1513.	0.9	1
197	Hypothyroidism-induced Reversible Encephalopathy as a Cause of Aggravation of Parkinsonism and Myoclonus in Parkinson's Disease. Tremor and Other Hyperkinetic Movements, 2017, 7, 505.	1.1	1
198	Development of Clinical Milestones in Parkinsonâ€™s Disease After Bilateral Subthalamic Deep Brain Stimulation. Journal of Movement Disorders, 2022, 15, 124-131.	0.7	1

#	Article	IF	Citations
199	Novel pattern of levodopa-related motor fluctuations: â€˜Paradoxicalâ€™ on. Parkinsonism and Related Disorders, 2008, 14, 281-285.	1.1	0
200	Posttraumatic hemiballism with focal discrete hemorrhage in contralateral subthalamic nucleus. Parkinsonism and Related Disorders, 2009, 15, 331.	1.1	0
201	Does Intraoperative Computed Tomography Obviate the Need for Postoperative Imaging Studies in Deep Brain Stimulation Surgery?. Neurosurgery, 2011, 69, E790-E791.	0.6	0
202	Young-onset multiple system atrophy. Journal of the Neurological Sciences, 2012, 323, 265.	0.3	0
203	RE: Response to â€œAcupuncture: It is time for scientifically well-designed studyâ€• Parkinsonism and Related Disorders, 2013, 19, 1179.	1.1	0
204	Corrigendum to â€œMusculoskeletal problems in Parkinson's disease: neglected issuesâ€•[Parkinsonism Relat Disord 19 (2013) 666â€“669]. Parkinsonism and Related Disorders, 2014, 20, 942.	1.1	0
205	Youngâ€•onset multiple system atrophy: Its rarity and heterogeneity. Movement Disorders, 2019, 34, 1085-1086.	2.2	0
206	Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?. Movement Disorders, 2020, 35, 901-902.	2.2	0
207	A Case of AOA2 With Compound Heterozygous <i>SETX</i> Mutations. Journal of Movement Disorders, 2021, , .	0.7	0